<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605694</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-145-21</org_study_id>
    <secondary_id>2015-004729-15</secondary_id>
    <nct_id>NCT02605694</nct_id>
  </id_info>
  <brief_title>Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)</brief_title>
  <official_title>A Phase 2, Randomized Study of Duvelisib Administered in Combination With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study to evaluate the efficacy and safety of DR vs R-CHOP in subjects with
      relapsed/refractory FL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2, randomized, two-arm, open-label study designed to evaluate the efficacy
      and safety of Duvelisib Administered in Combination with Rituximab vs R-CHOP in Subjects with
      Relapsed/Refractory Follicular Lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor is focusing on studies which can enable registration of duvelisib
  </why_stopped>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Time from randomization to documented disease progression, or death due to any cause, whatever comes first, assessed up to approximately 44 months.</time_frame>
    <description>Progression Free Survival (PFS), defined according to the revised International Working Group (IWG) criteria as assessed by the Independent Review Committee (IRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>Every 3-6 Cycles (Cycles 1-6 are 21-days; after Cycle 7 are 28-days) from randomization until first documented progression. Subjects will be evaluated for progression or the primary analysis of PFS, whichever occurs first.</time_frame>
    <description>Complete Response Rate (CRR) with complete response defined according to the revised IWG criteria as assessed by the IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Every 3-6 Cycles (Cycles 1-6 are 21-days; after Cycle 7 are 28-days) from randomization until first documented progression or the primary analysis of PFS, whichever occurs first.</time_frame>
    <description>ORR defined as best response of complete response (CR) or partial response/remission (PR), according to the revised IWG criteria as assessed by the IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Every 6 months until the primary analysis for PFS or 3 years from randomization, whichever occurs later.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Treatment Emergent Adverse Events (TEAEs) and changes in safety laboratory values as assessed by NCI-CTCAE, version 4.03)</measure>
    <time_frame>Continuous from informed consent until 30 days from last dose</time_frame>
    <description>Adverse events (AEs) and abnormal laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Evaluate the Duvelisib concentration in plasma sample</measure>
    <time_frame>Cycle 1 Day 15, Cycle 2 Day 1 and 15 (Cycles 1-6 are 21-day cycles)</time_frame>
    <description>Evaluate the Duvelisib concentration in plasma sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Every 3-6 Cycles (Cycles 1-6 are 21-days; after Cycle 7 are 28-days) from the first documented response to first documented progression or death, whichever occurs first.</time_frame>
    <description>DOR defined as the time from the first documented response to the first documentation of progressive disease (PD) according to the revised IWG criteria or death due to any cause (for subjects with CR or PR only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Evaluate IPI-656 (metabolite) concentration in plasma sample</measure>
    <time_frame>Cycle 1 Day 15, Cycle 2 Day 1 and 15 (Cycles 1-6 are 21-day cycles)</time_frame>
    <description>Evaluate IPI-656 (metabolite) concentration in plasma sample</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity; and Rituximab (375 mg/m2) will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R-CHOP will be administered as follows:
IV infusion on Day 1 of Cycles 1-6 (21-day cycles)
Cyclophosphamide (750 mg/m2)
Doxorubicin hydrochloride (50 mg/m2)
Vincristine sulfate (1.4 mg/m2) (2 mg maximum)
Rituximab (375 mg/m2) Orally on Days 1-5 of Cycles 1-6 (21-day cycles)
Prednisone (100 mg) will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>IPI-145</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>MabThera</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>IV infusion on Day 1 of Cycles 1-6 (21-day cycles)
Cyclophosphamide (750 mg/m2)
Doxorubicin hydrochloride (50 mg/m2)
Vincristine sulfate (1.4 mg/m2) (2 mg maximum)
Rituximab (375 mg/m2)</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Rituximab</other_name>
    <other_name>CHOP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Deltasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of FL: Grade 1, 2, or 3a

          2. Progressed within 24 months of initiating an alkylator-based chemotherapy regimen
             given as either first- or second-line therapy; single-agent chlorambucil therapy does
             not fulfill this requirement Note: subjects must have received at least 2 cycles of
             alkylator-based chemotherapy to be eligible

          3. Previously received rituximab, either as single agent or as part of any combination
             regimen, and also meet one of the following requirements:

               1. Progressed within 24 months of initiating alkylator-based chemotherapy in the
                  first line and received no additional anticancer therapy

               2. Progressed within 24 months of initiating alkylator-based chemotherapy in the
                  first line and subsequently progressed within 24 months of receiving any
                  second-line treatment and received no additional anticancer therapy

               3. Progressed within 24 months of initiating alkylator-based chemotherapy in the
                  second line and received no additional anticancer therapy

          4. Appropriate to receive R-CHOP

          5. At least 1 measurable disease lesion &gt; 1.5 cm in at least one dimension by computed
             tomography (CT), CT-PET, or magnetic resonance imaging (MRI)

          6. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (corresponds to
             Karnofsky Performance Status [(KPS) ≥60%])

          7. For women of childbearing potential (WCBP): negative serum β human chorionic
             gonadotropin (βhCG) pregnancy test within 1 week before first treatment (WCBP defined
             as a sexually mature woman who has not undergone surgical sterilization or who has not
             been naturally post-menopausal for at least 12 consecutive months for women &gt;55 years
             of age)

        Exclusion Criteria:

          1. Clinical evidence of transformation to a more aggressive subtype of lymphoma or grade
             3B FL

          2. Received ≥ 3 previous anticancer regimens prior to enrollment

          3. Received prior R-CHOP therapy

          4. Previous receipt of any anthracycline

          5. Contraindication to any of the individual components of CHOP (cyclophosphamide,
             vincristine, doxorubicin and prednisone) Severe allergic or anaphylactic reaction to
             any monoclonal antibody therapy, murine protein, or known hypersensitivity to any of
             the study drugs

          6. Received prior allogeneic transplant

          7. Received prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor

          8. History of tuberculosis treatment within the two years prior to randomization

          9. History of chronic liver disease, veno-occlusive disease, alcohol abuse

         10. Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic
             steroids &gt;20 mg of prednisone (or equivalent) QD

         11. Ongoing treatment for systemic bacterial, fungal, or viral infection at screening

         12. Concurrent administration of medications or foods that are strong inhibitors or
             inducers of cytochrome P450 3A (CYP3A)

         13. Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV),
             or herpes zoster (VZV) at screening

         14. Concurrent active malignancy other than nonmelanoma skin cancer, carcinoma in situ of
             the cervix

         15. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia
             requiring medication or a pacemaker within the last 6 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

